News
12-10-2009, 10:41 PM
Merck KGaA, Darmstadt, Germany, today announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC).
More... (http://www.news-medical.net/news/20091211/Initiation-of-multi-national-Phase-III-study-of-Stimuvax-announced.aspx)
More... (http://www.news-medical.net/news/20091211/Initiation-of-multi-national-Phase-III-study-of-Stimuvax-announced.aspx)